Search for
Menu
Entrepreneurs
Working with Us
Mentor Program for Studio Clients
Internship Program for Studio Clients
Diversity, Equity and Inclusion Grant
Entrepreneur Toolkit
Corporates
Investors
Portfolio
About
Team
Partners
Rev1 Labs Innovation Center
Jobs
Events
Blog
Get Started
Home
Entrepreneurs
Corporates
Investors
Portfolio
About
Get Started
Jobs
Events
Rev1 Labs
Blog
Entrepreneur Toolkit
Search for
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
By
Rev1 Staff
on
10/06/2016
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
Milo Biotechnology Announces FDA Orphan Drug Designation for Treatment of Inclusion Body Myositis
Comments are closed.
